Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275659 | 1.00 | SIGMAR1 (0.49) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| SCHEMBL2941954 | 1.00 | SIGMAR1 (0.49) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| SCHEMBL16657557 | 1.00 | SIGMAR1 (0.49) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| SCHEMBL14680382 | 1.00 | SIGMAR1 (0.49) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| Hydrochloric Acid SCHEMBL1373261 | 0.98 | SIGMAR1 (0.47) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| SCHEMBL25452990 | 0.92 | SIGMAR1 (0.44) | SIGMAR1SLC6A9HSD17B10TACR1DAO | |
| SCHEMBL14680427 | 0.92 | SIGMAR1 (0.44) | SIGMAR1SLC6A9HSD17B10HRH3S1PR1 | |
| SCHEMBL21335347 | 0.92 | SIGMAR1 (0.44) | SIGMAR1SLC6A9HSD17B10TACR1DAO | |
| SCHEMBL22871959 | 0.92 | SIGMAR1 (0.59) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 | |
| SCHEMBL14725157 | 0.92 | SIGMAR1 (0.59) | SIGMAR1SLC6A9HSD17B10TACR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023116856-A1 | AROMATIC VINYL COMPOUND, METAL COMPLEX THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海再极医药科技有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2022269532-A1 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AND NEURODEGENERATIVE DISORDERS | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2022-12-29 | — | — | WO | disclosed |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-01-20 | — | — | US | disclosed |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210008232-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | disclosed |
| US-20200231543-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-23 | — | — | US | disclosed |
| US-10696631-B2 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190084931-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | US HEALTH | 2019-03-21 | — | — | US | disclosed |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170296683-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170296683-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9388144-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-03-19 | — | — | US | disclosed |
| US-8926944-B2 | Radiolabeled prostate specific membrane antigen inhibitors | MOLECULAR INSIGHT PHARMACEUTICALS (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084931-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | H1-4, VIP, H1-3 | SIGMAR1 1479/4885SLC6A9 1477/4885HSD17B10 3363/4885 |
| US-20130034494-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA1 | SIGMAR1 3926/4885SLC6A9 2152/4885HSD17B10 2374/4885 |
| US-20210338850-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | SIGMAR1 2691/4885SLC6A9 3892/4885HSD17B10 3488/4885 |
| US-20150078998-A1 | RADIOLABELED PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, PSMA2 | SIGMAR1 3188/4885SLC6A9 2200/4885HSD17B10 1970/4885 |
| US-11712485-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA2, PSMA5, PSMA1 | SIGMAR1 2691/4885SLC6A9 3892/4885HSD17B10 3488/4885 |
| US-20170296683-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | SIGMAR1 2691/4885SLC6A9 3892/4885HSD17B10 3488/4885 |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | RABL3, H1-4, SSTR3 | SIGMAR1 1083/4885SLC6A9 1357/4885HSD17B10 3981/4885 |
| US-20210008232-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | KLK3, MAN2B2, BPHL | SIGMAR1 2116/4885SLC6A9 1037/4885HSD17B10 3229/4885 |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | NUCB2, RNPEP, MME | SIGMAR1 4015/4885SLC6A9 1965/4885HSD17B10 2830/4885 |
| US-10201624-B2 | Triazine based radiopharmaceuticals and radioimaging agents | PSMA5, PSMA2, PSMA1 | SIGMAR1 3683/4885SLC6A9 4615/4885HSD17B10 2654/4885 |
| US-20200231543-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | RABL3, H1-4, SSTR3 | SIGMAR1 1083/4885SLC6A9 1357/4885HSD17B10 3981/4885 |
| US-10696631-B2 | Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents | H1-4, VIP, H1-3 | SIGMAR1 1479/4885SLC6A9 1477/4885HSD17B10 3363/4885 |
| US-20190134237-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA2, PSMA5, PSMA1 | SIGMAR1 2691/4885SLC6A9 3892/4885HSD17B10 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.